• Business & Finance

    Ocugen Provides Business Update and Second Quarter 2021 Financial Results

    Conference Call and Webcast Today at 8:30 a.m. ET Rolling regulatory submission to Health Canada completed and review process initiated; U.S. FDA talks continue Multiple milestones achieved across regulatory and supply chain to support potential commercialization of pipeline assets The Company experienced organizational growth to reflect new business requirements in clinical development, manufacturing, and commercialization MALVERN, Pa., Aug. 06, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today reported second quarter 2021  

    Comments Off on Ocugen Provides Business Update and Second Quarter 2021 Financial Results
  • Business & Finance

    RiverNorth Specialty Finance Corporation Announces Final Results of Repurchase Offer

    CHICAGO–(BUSINESS WIRE)–RiverNorth Specialty Finance Corporation (the “Fund”) (NYSE: RSF), a closed-end fund, announced the final results of its repurchase offer for up to 5%, or 227,380 of its outstanding common shares. The repurchase offer expired at 5:00 P.M. Eastern Time on July 7, 2021. Based on information provided by DST Systems, Inc., the depositary for the repurchase offer, a total of 2,645,722 shares were submitted for redemption and 227,380 shares were repurchased. In accordance with the terms and conditions of the repurchase offer, because the number of shares submitted for redemption exceeds the number of shares offered to  

    Comments Off on RiverNorth Specialty Finance Corporation Announces Final Results of Repurchase Offer
  • Business & Finance

    NuCana Reports First Quarter 2021 Financial Results and Provides Business Update

    Bloomberg Deutsche Bank’s Nightmare Decade Is Gone, But Not Yet Forgotten (Bloomberg) — On the day before one of the biggest margin calls in history, Deutsche Bank AG chief Christian Sewing joined an urgent meeting with a not-unfamiliar message: there was a problem, and billions of dollars were at stake.But as executives on the late-March call briefed him on the bank’s exposure to Archegos Capital Management, this time it wasn’t all bad news. Risk managers had been concerned by the family office’s rapid growth for some time, and had been collecting additional collateral. And the firm’s traders stood ready to  

    Comments Off on NuCana Reports First Quarter 2021 Financial Results and Provides Business Update
  • Business News

    Luminar Provides Business Update and First Quarter Results

    Luminar Technologies, Inc. (“Luminar” or the “Company”) (NASDAQ: LAZR), the global leader in automotive lidar hardware and software technology, today announced a quarterly business update and financials for the first quarter ended March 31, 2021. “We’ve remained relentlessly focused on execution, hitting our key product, commercial, production and financial targets so far. This puts Luminar on track to meet or beat our 2021 company-level milestones from the beginning of the year, as we continue to extend our technology, product, and market leadership positions.” — Austin Russell, Founder & CEO Execution: Product, Industrialization, and Series Production Luminar continues to scale its  

    Comments Off on Luminar Provides Business Update and First Quarter Results
  • Business & Finance

    Valneva Reports Q1 2021 Financial Results and Business Update

    Excellent progress on clinical programs in the first quarter of 2021 for: VLA15, currently the only clinical stage vaccine candidate against Lyme disease VLA2001, currently the only inactivated, adjuvanted vaccine candidate for COVID-19 in clinical trials in Europe: Initiation of pivotal Phase 3 clinical trial Participation in the world’s first COVID-19 vaccine booster trial in the UK Publication of Phase 1/2 results VLA1553, currently the only Phase 3 chikungunya vaccine program worldwide Successful Nasdaq listing (Q2 event); $107.6 million of gross proceeds raised in a US initial public offering and a concurrent private placement in Europe Cash and cash equivalents  

    Comments Off on Valneva Reports Q1 2021 Financial Results and Business Update